Compare Abeona Therapeutics Inc (ABEO) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs D Wave Quantum Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while D Wave Quantum Inc trades at $20.31 (market cap $7.80B). The key difference: D Wave Quantum Inc is far larger — about 20.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | QBTS | |
|---|---|---|
Market Cap | $373.32M | $7.80B |
Sector | Health | Technology |
52-Week High | $7.23 | $44.78 |
52-Week Low | $4.17 | $12.98 |
Enterprise Value | $228.22M | $7.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
D-Wave Quantum (QBTS) trades at $22.56, up 0.11% on the day, amid a bearish technical signal from moving averages. The company reported a net loss of $355.06 million on $24.59 million revenue in 2025, with a negative net income margin of -2,957.23%. Recent positive developments include being named a Leader in the IDC MarketScape quantum computing assessment and securing a $1.5 million NSF grant.
Despite unanimous analyst buy ratings and a $39.86 consensus price target, significant risks include extreme cash burn, negative profitability, and the speculative nature of quantum computing commercialization. The stock's high P/S ratio of 619.05 reflects growth expectations but underscores valuation sensitivity to execution milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
